Rifampicin and colistin in the treatment of infections from multiresistant acinetobacter baumannii

Nosocomial infections by Acinetobacter baumannii are responsible for an increase in mortality and the duration of hospitalization. Imipenem represented during main years the 'Gold standard' in the treatment of infections due to Acinetobacter baumannii, however the emergence of resistances to this molecule in many hospitals constitutes a significant therapeutic challenge. The good sensitivity of this germ invitro to colistine, increased by the association of rifampicine supported the intravenous use of these antibiotics in vivo. We report our experience with rifampicine-colistine association for the treatment of infections due to Acinetobacter baumannii multiresistant in the surgical resuscitation unit of the CHU Sahloul of Sousse

Group A streptococci in children with acute pharyngitis in Sousse, Tunisia

A 1-year prospective study in 2 paediatric outpatient clinics in Sousse, Tunisia, aimed to determine the presence of group A streptococci in acute pharyngitis cases and carriers, and the distribution of the serotypes and biotypes. Group A streptococci were found in 9.0% of throat swabs from 155 controls and 17.7% from 474 patients [P < 0.05]. Of 43 strains isolated from patients and submitted for typing, 15 different types were identified, the most common being M75 [14 strains; 32.5%], M9 [6 strains; 14.0%], M76 [5 strains; 11.6%] and M12 [4 strains; 9.3%]. Three strains were non-typeable [7.0%]. Biotyping of the strains showed 3 predominant biotypes: biotype 3 [n = 14], biotype 2 [n = 11], and biotype 1 [n = 7]